Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valdoxan in everyday clinical practice for major depressive episode
ISRCTN68100949Phase 4Completed
- Sponsor
- Servier
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of agomelatine in major depressive disorder (MDD), sponsored by Servier. Primary endpoints: Clinical Global Impression Improvement response at week 6, Patient Global Impression Improvement response at week 6 and 2 more. Started Apr 2009; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN68100949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN68100949.